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Abstract
Chronic hepatitis B virus (HBV) infection is a major 
cause of cirrhosis and hepatocellular carcinoma (HCC). 
Applying the same strategies for antiviral therapy 
and HCC surveillance to all chronic hepatitis B (CHB) 
patients would be a burden worldwide. To properly 
manage CHB patients, it is necessary to identify and 
classify the risk for HCC development in such patients. 
Several HCC risk scores based on risk factors such 
as cirrhosis, age, male gender, and high viral load 
have been used, and have negative predictive values 
of ≥ 95%. Most of these have been derived from, 
and internally validated in, treatment-naïve Asian 
CHB patients. Herein, we summarized various HCC 
prediction models, including IPM (Individual Prediction 
Model), CU-HCC (Chinese University-HCC), GAG-HCC 
(Guide with Age, Gender, HBV DNA, Core Promoter 
Mutations and Cirrhosis-HCC), NGM-HCC (Nomogram-
HCC), REACH-B (Risk Estimation for Hepatocellular 
Carcinoma in Chronic Hepatitis B), and Page-B score. 
To develop a noninvasive test of liver fibrosis, we 
also introduced a new scoring system that uses liver 
stiffness values from transient elastography, including 
an LSM (Liver Stiffness Measurement)-based model, 
LSM-HCC, and mREACH-B (modified REACH-B). 
Key words: Chronic hepatitis B; Hepatocellular carcinoma; 
Development; Prediction models
MINIREVIEWS
Submit a Manuscript: http://www.wjgnet.com/esps/
Help Desk: http://www.wjgnet.com/esps/helpdesk.aspx
DOI: 10.3748/wjg.v22.i37.8314
8314 October 7, 2016|Volume 22|Issue 37|WJG|www.wjgnet.com
World J Gastroenterol  2016 October 7; 22(37): 8314-8321
 ISSN 1007-9327 (print)  ISSN 2219-2840 (online)
© 2016 Baishideng Publishing Group Inc. All rights reserved.
© The Author(s) 2016. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: This is the summary about prediction models 
of hepatocellular carcinoma development in chronic 
hepatitis B patients.
Lee HW, Ahn SH. Prediction models of hepatocellular 
carcinoma development in chronic hepatitis B patients. World J 
Gastroenterol 2016; 22(37): 8314-8321  Available from: URL: 
http://www.wjgnet.com/1007-9327/full/v22/i37/8314.htm  DOI: 
http://dx.doi.org/10.3748/wjg.v22.i37.8314
INTRODUCTION
Chronic hepatitis B virus (HBV) infection is the main 
cause of cirrhosis, hepatic failure, and hepatocellular 
carcinoma (HCC) globally[1]. Of chronic HBV carriers, 
approximately 15%-40% develop chronic hepatitis 
B (CHB)[2]. Around 90% of CHB patients undergo 
seroconversion of HBeAg to anti-HBe and become 
inactive carriers. However, approximately 10% of CHB 
patients have chronic active hepatitis and develop 
liver cirrhosis at a rate of 2% per year. Because 
progression of liver disease in CHB patients is closely 
associated with active viral replication, a high level 
of HBV DNA has been known as an independent risk 
factor for disease progression. Therefore, suppression 
of HBV with antiviral therapy could reduce the risk of 
developing cirrhosis and HCC.
The development of potent antiviral drugs has 
an important role in the management of patients 
with CHB. The natural course of the disease could 
be modified by HBV therapy and risk for HCC could 
be reduced[3-5]. Antiviral therapy reduces, but does 
not completely eliminate risk for HCC[6,7]. The annual 
incidence of HCC range from 0.01% to 5.4% in 
CHB patients treated with entecavir or tenofovir[8]. 
Therefore, applying a standardized policy for antiviral 
therapy and HCC surveillance to all CHB patients may 
not be cost-effective[9]. Thus, stratification of the risk 
for HCC development is important for the management 
of CHB patients.
This review summarizes the prediction models of 
HCC development in CHB patients.
RISK FACTORS FOR HBV-RELATED HCC
Risk factors for disease progression in CHB can be 
classified into three categories: host factors, viral factors 
and liver factors[4,10,11]. Host factors include older age, 
male gender, family history of HCC, obesity, genetic 
susceptibility such as single-nucleotide polymorphisms, 
cirrhosis, smoking, alcohol, diabetes mellitus and 
immune status[11-16]. Viral factors include a high level of 
HBV DNA, positive hepatitis B virus e antigen (HBeAg), 
HBV genotype, HBV mutants, and a high serum level 
of hepatitis B surface antigen (HBsAg)[16-22]. Particularly, 
an increasing viral load is a strong predictor of the risk 
for HCC independent of HBeAg, aminotransferase, 
and cirrhosis[12,13,18,23]. Liver factors consist of advance 
fibrosis and cirrhosis, poor liver function, active 
hepatitis, and other concomitant liver diseases such 
as co-infection with hepatitis C virus or, alcoholic and 
nonalcoholic fatty liver diseases[11-13,24-26].
The progression of liver disease in chronic HBV 
infection is mediated by active virus replication. The 
annual incidence of cirrhosis in the overall population 
with CHB is 2%-7%, depending on viral replication 
status[27]. In particular, disease progression is markedly 
accelerated in patients with active viral replication by up 
to 15%-20%. Currently, a complete virological response 
(CVR) can be achieved even in CHB patients using 
potent antiviral therapy. Thus, the prognostic value of 
the baseline level of HBV DNA, which was suggested by 
large-scale studies to be a robust prognostic indicator 
of the “natural” course of chronic HBV infection before 
the era of antiviral treatment, is limited[28]. In the era of 
antiviral therapy, the prognostic significance of serum 
levels of HBV DNA has substantially diminished, because 
most treated patients achieve a virological response[28]. 
More importantly, the risk for developing liver-related 
events cannot be completely eliminated even in those 
who achieve a complete virological response; thus, 
caution is required in so-called “high-risk” patients who 
may experience disease progression.
APPROACHES TO DEVELOPING RISK 
SCORES
Factors independently associated with HCC are first 
identified in a training or derivation cohort[4,16]. Second, 
scores are assigned to different parameters in the 
equation to generate the final score. This score is 
validated in a validation cohort to demonstrate its 
applicability and reproducibility. If no independent 
cohort is available, external validation can be applied 
to assess the performance of the score in new data. 
This validation involves using a single observation from 
the original sample as the validation data, and the 
remaining observations as the training data. This is 
repeated such that each observation is used as training 
and validation data.
Validation of the score usually includes discrimination 
and calibration. Discrimination can be assessed using 
a receiver operating characteristic (ROC) curve, sen-
sitivity, and specificity[29,30]. Calibration is evaluated by 
estimating the observed HCC risk using the Kaplan-
Meier method with the same cumulative risk scores. A 
combination of neighboring groups of cumulative risk 
scores will be performed if the observed HCC risk in a 
group with the same cumulative risk score is low[4,13].
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HCC RISK SCORES
Until now, several HCC risk prediction scoring systems 
have been derived to estimate the risk for HCC 
development in CHB from baseline parameters[11-13,31]. 
Almost all the scores were derived from and internally 
validated in treatment-naïve Asian CHB patients[23]. 
Besides, external validation has been limited to Asian 
CHB patients or those undergoing treatment with 
entecavir. Studies including European Caucasian and 
American patients have shown the models to be 
somewhat less predictive; however, rates of HCC were 
very low, significantly limiting the conclusions[6,32].
Individual prediction model
Based on the risk factors of 4339 Korean patients, 
the individual prediction model (IPM) was developed 
by calculating the relative weights of risk factors, and 
a screening program for HCC was established[33]. Old 
age, male gender, initial serum AFP level, platelet 
count, serum albumin, severe liver parenchymal 
echogenic pattern in ultrasonography and heavy alcohol 
consumption were significant risk factors for HCC. 
Based on these risk factors, the IPM was calculated 
using the following formula: risk index (RI) for HCC = 
eA, A = -6.2543 + (1.7219 × liver cirrhosis) + (1.3145 
× old age over 40 years) + (1.2631 × chronic HCV 
infection) + (0.8257 × AFP > 20 ng/mL) + (0.7754 × 
chronic HBV infection) + (0.7339 × chronic hepatitis) 
+ (0.5840 × heavy alcoholics) + (0.3 × man) + 
(0.2830 × ALT > 40 IU/L) + (0.221 × unknown 
alcohol history). Probability for HCC = RI/(1 + RI). The 
authors prospectively applied the screening program 
to 833 patients with chronic liver disease stratified into 
three groups [a low-risk group (< 5% probability), an 
intermediate group (5%-15% probability), and high-risk 
group (> 15% probability)] by IPM. The patients were 
followed, at intervals that varied according to the risk 
index. According to IPM, 2 of 324 patients in the low-risk 
group (0.62%), 20 of 413 patients in the intermediate-
risk group (4.8%), and 22 of 96 patients in the high-
risk group (22.9%) were diagnosed with HCC. Thus, the 
screening program based on IPM enabled cost-effective 
prediction of the risk of developing of HCC by focusing 
on the high-risk group.
CU-HCC score
The Chinese University (CU)-HCC score was first 
derived using a cohort of 1005 Chinese CHB patients 
that had undergone HCC surveillance at the Chinese 
University of Hong Kong[4,12,25]. It was validated in an 
independent cohort of 424 Chinese CHB patients[34]. All 
patients were treatment-naïve at baseline. Among the 
patients in the training and validation cohort, 15.1% 
and 25.0%, respectively, received antiviral therapy 
during the long-term follow-up. The CU-HCC score 
is composed of five factors: age, albumin, bilirubin, 
HBV DNA, and cirrhosis; it ranges from 0 to 44.5. 
Two cutoff values (5 and 20) discriminated HCC risk 
into three categories. In all, 105 (10.4%) patients in 
the training cohort and 45 (10.6%) patients in the 
validation cohort developed HCC during a median of 
10 years of follow-up. The 5-year HCC-free survival 
rates were 98.3%, 90.5%, and 78.9% in the low-, 
medium-, and high-risk groups, respectively. Using the 
lower cutoff of 5 points, this score has a high negative 
predictive value (97.8%) for excluding future HCC 
development.
GAG-HCC score
The Guide with Age, Gender, HBV DNA, Core Promoter 
Mutations and Cirrhosis (GAG-HCC) score was 
developed from a cohort of 820 Chinese CHB patients 
from tertiary referral clinics[4,13]. All patients were 
treatment-naïve at baseline and followed-up for a 
median of 77 mo. There are two versions of the score. 
The original version is composed of five parameters: 
gender, age, core promoter mutations, levels of HBV 
DNA, and cirrhosis. Because the test for core promoter 
mutations may not be available in some centers, the 
score was simplified to omit such mutations. The score 
can be above 100, as age is one of the components. A 
cutoff value of 100 had a sensitivity and specificity of 
84.1% and 76.2% for 5-year prediction, and 88.0% 
and 78.7% for 10-year prediction, respectively. The 
negative predictive values for excluding future HCC 
development were 98.3%-100%.
NGM1-HCC and NGM2-HCC
The risk evaluation of viral load elevation and 
associated liver disease (REVEAL)-HBV investigators 
first suggested easy-to-use nomograms based on 
noninvasive clinical characteristics using data from 
3653 patients[31]. Previously confirmed independent 
risk predictors were sex, age, family history of 
HCC, alcohol consumption habit, ALT level, HBeAg 
serostatus, levels of HBV DNA, and HBV genotype. 
Regression coefficients were rounded to integer risk 
scores, and the predicted risk over 5- and 10-year 
periods for each risk score was calculated and depicted 
as nomograms. Nomogram 1 and Nomogram 2 
hepatocellular carcinoma (NGM1-HCC and NGM2-HCC) 
were used to calculate individual baseline risk scores 
for each patient[31]. The patients were categorized 
into low-, medium- and high-risk groups to facilitate 
comparison of the risk scores using the different 
prediction models, and to simplify their use in the 
clinical setting. The correlation coefficients between 
observed HCC risk and the nomogram-predicted risk 
were greater than 0.90.
REACH-B score
The risk estimation for hepatocellular carcinoma in 
chronic hepatitis B (REACH-B) score was derived using 
3584 Chinese CHB patients from the Taiwanese REVEAL 
cohort, and validated in a cohort of 1505 patients from 
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XL probe could be helpful to check liver stiffness[42,43]. 
Especially, the presence of nonhepatic ascites does 
not affect underlying liver stiffness by TE[42]. A liver 
stiffness value > 12 kPa or 13 kPa by TE can be used 
to detect histologic cirrhosis in patients with CHB[44,45]. 
Furthermore, recent studies have reported TE can 
predict the development of portal hypertension-related 
complications and HCC[46-48]. 
Liver stiffness measurement-based Model
Stratified baseline liver stiffness values in patients 
with CHB are independent predictors of HCC 
development[38]. The 3-year cumulative incidence of 
HCC is significantly higher in patients with a higher 
liver stiffness value[38]. Kim et al[49] prospectively 
analyzed 1110 patients with CHB who received a 
transient elastography and were available for inclusion 
criteria from May 2005 to December 2007.
A previous multivariate analysis showed that age, 
male gender, and liver stiffness values independent 
predictors of HCC (all P < 0.05). In addition, HBV DNA 
levels ≥ 20000 IU/L showed borderline significance. 
Using these four variables, a predictive model was 
developed (AUROC 0.806, 95%CI: 0.738-0.874). The 
formula for a 3-year probability of HCC occurrence 
is as follows: Probability = 1 - PA [A = exp (0.05306 
× age + 1.106 × male gender + 0.04858 × liver 
stiffness values + 0.50969 × HBV DNA ≥ 20000 IU/L)]. 
In bootstrap analyses, the AUROC remained largely 
unchanged between iterations, with an average value 
of 0.802 (95%CI: 0.791-0.812). The predicted risk for 
HCC development calibrated well with the observed 
risk, with a correlation coefficient of 0.905 (P < 0.001).
LSM-HCC score
Wong et al[50] developed a new liver stiffness measure-
ment (LSM)-HCC score composed of LSM, age, serum 
albumin, and levels of HBV DNA. Because diagnosis of 
cirrhosis based on ultrasonography may be incorrect, 
cirrhosis as a factor of CU-HCC score was substituted 
by LSM. Among 1555 CHB patients, 1035 and 520 
were assigned to the training and validation cohort, 
respectively. During a mean of 69 months of follow-up, 
38 (3.7%) patients in the training cohort and 17 (3.4%) 
patients in the validation cohort developed HCC. The 
LSM-HCC score ranged from 0 to 30. Using 11 as the 
cutoff value, 706 (68.2%) and 329 (31.8%) patients 
were in the low- and high-risk categories; 4 (0.6%), 
and 29 (8.8%) patients developed HCC over 5 years. 
The AUROCs of the LSM-HCC score were higher than 
those of the CU-HCC score (0.83-0.89 vs 0.75-0.81). 
The sensitivity for identifying HCC was 87.9% and the 
NPV was 99.4% at 5 years. 
Modified REACH-B score
The REACH-B scoring system, which was developed 
and validated as a simple HCC prediction model prior 
to the era of antiviral therapy, showed suboptimal 
three tertiary referral clinics in Hong Kong and South 
Korea[4,11]. The patients in the training cohort did not 
have cirrhosis at the time of recruitment, and remained 
treatment-naïve throughout the 12-year follow-up 
period. Variables included in the risk score were sex, 
age, serum levels of alanine aminotransferase, HBeAg 
status, and levels of HBV DNA level. In all, 131 (3.7%) 
patients in the training cohort and 111 (7.4%) patients 
in the validation cohort were developed HCC. A 17-point 
risk score was developed and HCC risk ranged from 0% 
to 23.6% at 3 years, 0% to 47.4% at 5 years, and 0% 
to 81.6% at 10 years for patients with the lowest and 
highest HCC risks, respectively. The score accurately 
estimated the risk for developing HCC at 3, 5, and 
10 years in patients with CHB. A revised version of 
REACH-B that includes serum levels of qHBsAg is also 
available[35]. 
PAGE-B score
Previous risk scores have been developed mainly in 
Asians. Therefore, these scores may not be suitable 
for Caucasian patients with CHB. A new score named 
PAGE-B has recently been developed for Caucasian 
CHB patients[36]. A nine-center cohort study was 
performed in Caucasian CHB patients treated with 
oral antivirals[36]. They included 1815 adult CHB 
patients without baseline HCC who received entecavir 
or tenofovir for more than 1 year. The PAGE-B score 
was developed based on age, gender, and platelets. 
During a median of 50 months of follow-up, 51 
(3.8%) patients in the derivation group and 34 (6.9%) 
patients in the validation group developed HCC. 
Patients with PAGE-B scores of ≤ 9, 10-17, and ≥ 
18 had 5-year cumulative HCC incidences of 0%, 3% 
and 17%, respectively. In the validation cohort, the 
negative predictive value to exclude HCC using at a 
cut-off of 10 points approached 100%. This was the 
first study to develop an HCC risk score for Caucasian 
CHB patients and was the first score for patients 
treated with current first-line antiviral therapies.
LIVER STIFFNESS MEASUREMENT-
BASED MODELS
The degree of liver fibrosis is significantly related 
to risk for HCC development[37,38]. To date, the 
gold standard for evaluating the degree of fibrosis 
is liver biopsy. However, liver biopsy cannot be 
performed in all CHB patients in a clinical setting due 
to its invasiveness and complications[39]. Transient 
elastography (TE, FibroScan®, Echosens, Paris, 
France) has been validated as a noninvasive method 
for assessing fibrosis in chronic liver disease[40]. The 
advantage of TE include its noninvasiveness, highly 
reproducibility, and accuracy. TE is used as a reliable 
surrogate for liver biopsy to detect early cirrhosis in 
patients with CHB[41]. 
For patients with ascites or high BMI, the use of 
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predictive performance. Therefore, an alternative 
predictor of long-term prognosis is required particularly 
in CHB patients who had achieved CVR from antiviral 
treatment, because levels of HBV DNA are no longer 
useful at the time of CVR. 
In the modified REACH-B model (mREACH-B model), 
the serum levels of HBV DNA were substituted for the 
LS value, and had better predictive performance among 
patients who were at CVR following entecavir therapy[28]. 
The authors reassessed the scores at CVR, using LS values 
instead of suppressed HBV DNA. The AUROC value for 
risk at the 3-year follow-up was 0.805, compared to 0.629 
using the original REACH-B scoring system, when 0, 1, and 
2 points were assigned to LS values of < 8.0, 8.0-13.0, 
and > 13.0 kPa, respectively (referred to as the modified 
REACH-B I), and 0.814 (95%CI: 0.709-0.912) when 0, 2, 
and 4 points were assigned to LS values of < 8.0, 8.0-13.0, 
and > 13.0 kPa, respectively (referred to as the modified 
REACH-B II).
The performance of conventional HCC prediction 
models (CU-HCC, GAG-HCC, REACH-B, and LSM-
HCC scores) and the mREACH-B score has been 
assessed[51]. During the follow-up (median, 75.3 
mo), HCC developed in 125 (9.6%) of 1308 subjects. 
The mREACH-B score had a significantly higher 
AUROC for prediction of HCC development at 3/5 
years (0.828/0.806), compared to the LSM-HCC 
(0.777/0.759), GAG-HCC (0.751/0.757), REACH-B 
(0.717/0.699), and CU-HCC (0.698/0.700) scores (all 
P values < 0.05 vs mREACH-B). Thus, the prognostic 
performance of the mREACH-B score was superior to 
that of the conventional models. 
OTHER HCC RISK MODELS
Existing prediction models were mostly developed in 
Asia. There were limited data about HCC risk models 
for people at high risk in the United States or European 
countries. France group suggested PNPLA3 rs738409 
(GG) genotype had an effect on the occurrence of 
HCC[52]. They created the following model: age × 
0.05085 - 1.88790 × female gender + BMI × 0.09712 
+ rs738409 (GG) × 0.78377.
When applied to 250 patients with alcoholic 
cirrhosis, scores ranged from 2.20-9.25. The cut-off 
values for calculated score were below 5, between 5 
and 7, and above 7, respectively. 6-year incidence of 
HCC increased according to stratification of three risk 
groups. 
There was another risk prediction model sug-
gested from United States[53]. By Cox proportional 
hazards regression model, clinical and demographic 
data (including age, sex, smoking status, alkaline 
phosphatase level, and platelet count) and Epidermal 
Growth Factor Gene genotype (GG) was used to 
predict HCC risk. The cohort was stratified into three 
groups depending on the risk of HCC development.
CONCLUSION
This review summarizes prediction models of HCC 
development in CHB patients (Tables 1 and 2). HCC 
Lee HW et al . Prediction of HCC development
Table 1  Summary of hepatocellular carcinoma prediction models
IPM CU-HCC GAG-HCC REACH-B LSM-HCC mREACH-B PAGE-B
Full name Individual 
Prediction Model
Chinese 
University-HCC
Guide with 
Age, Gender, 
HBV DNA, 
Core Promoter 
Mutations and 
Cirrhosis-HCC
Risk Estimation 
for Hepatocellular 
Carcinoma in 
Chronic Hepatitis 
B
Liver Stiffness 
Measurement-
HCC
Modified Risk 
Estimation for 
Hepatocellular 
Carcinoma in 
Chronic Hepatitis 
B
Calculation Risk Index (RI) 
for HCC = eA, A = 
-6.2543 + (1.7219 
× liver cirrhosis) 
+ (1.3145 × old 
age over 40 yr) + 
(1.2631 × chronic 
HCV infection) + 
(0.8257 × AFP > 20 
ng/mL) + (0.7754 
× chronic HBV 
infection) + (0.7339 
× chronic hepatitis) 
+ (0.5840 × heavy 
alcoholics) + (0.3 
× man) + (0.2830 × 
ALT > 40 IU/L) + 
(0.221 × unknown 
alcohol history)
Age (> 50 yr = 3; ≤ 
50 = 0) + albumin 
(≤ 35 g/L = 20; > 
35 = 0) + bilirubin 
(> 18 µmol/L = 
1.5; ≤ 18 = 0) + 
HBV DNA (< 4 log 
copies/mL = 0; 
4-6 = 1; > 6 = 4) + 
cirrhosis (yes = 15; 
no = 0)
14 × sex (male = 
1; female = 0) + 
age (in years) + 3 
× HBV DNA (log 
copies/mL) + 33 × 
cirrhosis presence 
= 1; absence = 0)
Male sex: 2 points
Age: 1 point for 
every 5 yr from 35 
to 65 yr of age (0-6 
points)
ALT (IU/L): 
15-<45 (1 point), ≥ 
45 (2 points)
Positive HBeAg: 2 
points
HBV DNA (log 
copies/mL): 4-< 
5 (3 points), 5-< 6 
(5 points), ≥ 6 (4 
points)
Age (> 50 yr = 
10; ≤ 50 = 0) + 
albumin (≤ 35 
g/L = 1; > 35 = 0) 
+ HBV DNA (> 
200000 IU/mL = 
5; ≤ 200000 = 0) 
+ liver stiffness 
(≤ 8.0 kPa = 0; < 
8.0-12.0 = 8; > 12.0 
= 14)
Male sex: 2 points
Age: 1 point for 
every 5 yr from 35 
to 65 yr of age (0-6 
points)
ALT (IU/L): 15-< 
45 (1 point), ≥ 45 (2 
points)
Positive HBeAg: 2 
points
Liver stiffness 
values: < 8.0 kPa (0 
point), 8.0-13.0 (2 
points), > 13.0 kPa 
(4 points)
Age;
< 30 (-4 points),
30-39 (-2 points),
40-49 (0 point),
50-59 (2 points),
60-69 (4 points),
≥ 70 (6 points)
Male sex:
5 points
Platelets (mm3):
≥ 200 × 103 (0 
point),
100× 103-< 200 × 
103 (6 points),
< 100 × 103 (11 
points)
HCC: Hepatocellular carcinoma; HBV: Hepatitis B virus; ALT: Alanine aminotransferase.
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risk scores can accurately predict subsequent HCC 
development in CHB patients. Different levels of care 
and different intensities of HCC surveillance should be 
offered according to the patient’s risk profile. Patients 
in the high-risk category should be offered antiviral 
therapy, as well as appropriate HCC surveillance. 
Effective suppression of HBV replication by antivi-
ral therapy can reduce risk for HCC development. 
However, antiviral therapy does not eliminate the 
HCC risk completely, because of the presence of virus 
integrated into the host genome. The HCC risk is 
higher in cirrhotic than non-cirrhotic patients. Antiviral 
therapy with no risk of resistance such as entecavir or 
tenofovir should be initiated before cirrhosis occurs.
HCC prediction models can help optimize antiviral 
therapy based on the level of HCC risk. It should be 
adjusted for patients who are already on treatment. 
Decisions regarding who needs treatment and regular 
surveillance should be individualized using HCC risk 
prediction models.
FUTURE PERSPECTIVES
In the future, a more accurate risk model that incor-
porates newly identified risk factors and somatic 
and inherited biomarkers (e.g., single-nucleotide 
polymorphisms, proteomics) is required for more 
accurate estimation of risk. Various plasma proteins have 
been proposed as new biomarkers of genetic background 
to predict development of HCC. These biomarkers are 
expected to guide individual surveillance or treatment 
for CHB patients. However, further functional studies 
are needed to validate these biomarkers. In addition, 
simple, user-friendly models for primary care providers 
would facilitate referral of high-risk patients. 
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